Gilead Sciences 2012 Annual Report Download - page 3

STRIBILD
New Tools for HIV Prevention
In July 2012, Truvada® became the first product
approved by FDA in combination with safer sex
practices to reduce the risk of HIV in uninfected
adults at high risk, a strategy called pre-exposure
prophylaxis (PrEP). At the 2012 International AIDS
Conference—the largest gathering of scientists,
clinicians, public health experts and advocates
committed to eradicating the disease—a sense of
growing optimism prevailed. The approval of Truvada
for PrEP was noted as a milestone that could help
slow the spread of HIV in communities at greatest
risk, offering new hope for bringing the epidemic
under control. While great progress in diagnosis and
linkage to care for individuals with HIV has occurred
in the last several years, HIV prevention remains a
challenge around the world.
Jamie was diagnosed with HIV in 2008. In order to cope with
the fear he experienced at the time of his diagnosis, Jamie
educated himself extensively about the disease and worked
closely with his doctor to find the right treatment. With
his doctor’s encouragement, he began antiretroviral
therapy right away. Today, among many other interests, Jamie
maintains a passion for travel and the outdoors—recently
visiting a small fishing village in Mexico and Patagonia.
Stribild® Approved for HIV
Because of their effectiveness, safety profiles
and convenience, single tablet regimens have
become a standard of care for HIV. A single
tablet regimen combining the multiple drugs
required for HIV treatment helps ensure
patients take all of their medicine, avoiding
partial doses which can lead to resistance
to therapy. To this end, in 2012 we achieved
a significant milestone: the approval by the
U.S. Food and Drug Administration (FDA)
of Stribild, a fixed-dose formulation of
four Gilead medicines in a once-daily pill
for treatment-naïve patients. It’s our third
single tablet regimen for HIV, joining Atripla®
and Complera,
® which are among the most-
prescribed antiretroviral regimens in the
United States and Europe.
DEDICATION:
HIV/AIDS AT
.A TURNING
POINT
2 3